The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis Ezzeldin M. IbrahimMeteb E. Al-FoheidiGhieth A. Kazkaz Review 01 November 2014 Pages: 467 - 476
Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets S. N. OnonyeW. ShiL. Pusztai Review 14 November 2014 Pages: 477 - 488
A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer Sepideh GholamiAndrew MaranoYuman Fong Preclinical study 13 November 2014 Pages: 489 - 499
Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models Ekram GadLauren RastetterMary L. Disis Preclinical Study 14 November 2014 Pages: 501 - 510
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study D. BalmativolaC. MarchiòA. Sapino Preclinical study Open access 14 November 2014 Pages: 511 - 523
Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy Minoru MiyashitaHironobu SasanoNoriaki Ohuchi Preclinical study 14 November 2014 Pages: 525 - 534
Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial Denise A. YardleyEric RaefskyAlejandro Inclan Clinical Trial 06 November 2014 Pages: 535 - 540
Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype Alexander M. Th. SchmitzClaudette E. LooKenneth G. A. Gilhuijs Clinical trial 07 November 2014 Pages: 541 - 551
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies Chris TwelvesJavier CortesAhmad Awada Clinical trial Open access 08 November 2014 Pages: 553 - 561
Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy Joanne MortimerJae JungSanjeet Dadwal Clinical trial Open access 11 November 2014 Pages: 563 - 570
Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer Leticia B. A. RangelJodi L. TarabaJohn G. Kuhn Clinical trial 14 November 2014 Pages: 571 - 580
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer C. PalmieriS. CleatorR. C. Coombes Clinical Trial 14 November 2014 Pages: 581 - 590
Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG) Emmanouil SaloustrosNikolaos MalamosDimitrios Mavroudis Clinical Trial 16 November 2014 Pages: 591 - 597
Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis C. A. DrukkerS. G. EliasE. J. Th. Rutgers Clinical trial 21 November 2014 Pages: 599 - 613
Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer Satish GuptaKatarzyna Jaworska-BieniekJakubowska Anna Epidemiology 07 November 2014 Pages: 615 - 622
Association of SULT1A1 Arg213His polymorphism with male breast cancer risk: results from a multicenter study in Italy L. OttiniP. RizzoloD. Palli Epidemiology 11 November 2014 Pages: 623 - 628
Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14 Anna CoppaAmelia BuffoneGiuseppe Giannini Epidemiology 14 November 2014 Pages: 629 - 635
Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast Jordan M. CloydRachel L. YangIrene L. Wapnir Epidemiology 16 November 2014 Pages: 637 - 644
Association between persistence with mammography screening and stage at diagnosis among elderly women diagnosed with breast cancer Ami VyasSuresh MadhavanUsha Sambamoorthi Epidemiology 16 November 2014 Pages: 645 - 654
Degree of urbanization and mammographic density in Dutch breast cancer screening participants: results from the EPIC-NL cohort Marleen J. EmausMarije F. BakkerCarla H. van Gils Epidemiology 16 November 2014 Pages: 655 - 663
Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer Gianluca SeveriMelissa C. SoutheyLaura Baglietto Epidemiology 19 November 2014 Pages: 665 - 673
Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers Werner PfeiferAnna P. SokolenkoEvgeny N. Imyanitov Brief Report 21 November 2014 Pages: 675 - 683
Concerns about methods for determination of estrogens in body fluids Robert T. ChattertonMiguel MuzzioPeter H. Gann Letter to the Editor 11 November 2014 Pages: 685 - 685
MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis Kukatharmini TharmaratnamAnne Irene HagenPål Møller Letter to the Editor Open access 15 November 2014 Pages: 687 - 688
The frequency of the BLM p.Q548X (c.1642C>T) mutation in breast cancer patients from Russia is no higher than in the general population Maksim S. AnisimenkoAnton E. KozyakovSergey P. Kovalenko Letter to the Editor 16 November 2014 Pages: 689 - 690
Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers Jennifer T. Loud Rebuttal Letter 18 November 2014 Pages: 691 - 692
The frequency of the BLM*p.Q548X (c.1642C > T) mutation in breast cancer patients from Russia Evgeny ImyanitovDarya ProkofyevaThilo Dörk Rebuttal Letter 20 November 2014 Pages: 695 - 696
Erratum to: Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours Brigid C. BrowneAlex J. EustaceNorma O’Donovan Erratum 04 November 2014 Pages: 697 - 697
